Ken Griffin Cytokinetics Inc Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cytokinetics Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 219,400 shares of CYTK stock, worth $9.53 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

219,400

Previous 166,800 31.53%

Holding current value

$9.53 Million

Previous $8.81 Million 17.18%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$46.36 - $58.62 $20.1 Million - $25.5 Million	434,454 Added 46.36%	1,371,645 $64.5 Million
Q3 2024 Nov 14, 2024	BUY	$51.22 - $60.16 $4.01 Million - $4.71 Million	78,218 Added 9.11%	937,191 $49.5 Million
Q2 2024 Aug 14, 2024	BUY	$47.86 - $75.05 $14.3 Million - $22.4 Million	298,071 Added 53.14%	858,973 $46.5 Million
Q1 2024 May 15, 2024	BUY	$63.75 - $108.06 $18.4 Million - $31.2 Million	288,309 Added 105.77%	560,902 $39.3 Million
Q4 2023 Feb 14, 2024	SELL	$26.88 - $83.49 $25.8 Million - $80.1 Million	-959,231 Reduced 77.87%	272,593 $22.8 Million
Q3 2023 Nov 14, 2023	BUY	$29.46 - $36.61 $9.78 Million - $12.1 Million	331,835 Added 36.87%	1,231,824 $36.3 Million
Q2 2023 Aug 14, 2023	BUY	$32.62 - $40.75 $29.4 Million - $36.7 Million	899,989 New	899,989 $29.4 Million
Q4 2022 Feb 14, 2023	SELL	$35.77 - $51.11 $14.9 Million - $21.3 Million	-417,392 Reduced 83.87%	80,263 $3.68 Million
Q3 2022 Nov 14, 2022	SELL	$38.54 - $54.52 $160 Million - $226 Million	-4,145,172 Reduced 89.28%	497,655 $24.1 Million
Q2 2022 Aug 15, 2022	BUY	$33.93 - $48.92 $148 Million - $214 Million	4,370,177 Added 1602.85%	4,642,827 $182 Million
Q1 2022 May 16, 2022	BUY	$29.74 - $46.0 $7.16 Million - $11.1 Million	240,717 Added 753.82%	272,650 $10 Million
Q4 2021 Feb 14, 2022	SELL	$34.35 - $46.38 $8.99 Million - $12.1 Million	-261,674 Reduced 89.12%	31,933 $1.46 Million
Q3 2021 Nov 15, 2021	BUY	$18.54 - $35.74 $3.83 Million - $7.38 Million	206,533 Added 237.19%	293,607 $10.5 Million
Q2 2021 Aug 16, 2021	SELL	$19.79 - $26.99 $4.64 Million - $6.33 Million	-234,642 Reduced 72.93%	87,074 $1.72 Million
Q1 2021 May 17, 2021	BUY	$18.57 - $25.68 $4.11 Million - $5.69 Million	221,545 Added 221.17%	321,716 $7.48 Million
Q4 2020 Feb 16, 2021	SELL	$15.26 - $28.61 $18.3 Million - $34.4 Million	-1,201,778 Reduced 92.31%	100,171 $2.08 Million
Q3 2020 Nov 16, 2020	BUY	$20.58 - $28.96 $12.8 Million - $18 Million	622,924 Added 91.74%	1,301,949 $28.2 Million
Q2 2020 Aug 14, 2020	SELL	$11.15 - $24.64 $5.42 Million - $12 Million	-485,691 Reduced 41.7%	679,025 $16 Million
Q1 2020 May 15, 2020	BUY	$8.75 - $16.3 $9.81 Million - $18.3 Million	1,121,024 Added 2565.74%	1,164,716 $13.7 Million
Q4 2019 Feb 14, 2020	SELL	$7.95 - $11.84 $85,907 - $127,943	-10,806 Reduced 19.83%	43,692 $464,000
Q3 2019 Nov 14, 2019	BUY	$10.82 - $14.25 $32,016 - $42,165	2,959 Added 5.74%	54,498 $620,000
Q2 2019 Aug 14, 2019	SELL	$7.95 - $11.25 $755,965 - $1.07 Million	-95,090 Reduced 64.85%	51,539 $580,000
Q1 2019 May 15, 2019	SELL	$5.95 - $10.19 $439,252 - $752,266	-73,824 Reduced 33.49%	146,629 $0
Q4 2018 Feb 14, 2019	BUY	$5.91 - $9.29 $921,085 - $1.45 Million	155,852 Added 241.25%	220,453 $1.39 Million
Q2 2018 Aug 10, 2018	SELL	$6.9 - $9.9 $1.43 Million - $2.06 Million	-207,868 Reduced 76.29%	64,601 $0
Q1 2018 May 11, 2018	SELL	$7.2 - $10.05 $1.08 Million - $1.5 Million	-149,708 Reduced 35.46%	272,469 $1.96 Million
Q4 2017 Feb 09, 2018	SELL	$7.25 - $15.65 $6 Million - $13 Million	-828,120 Reduced 66.23%	422,177 $3.44 Million
Q3 2017 Nov 09, 2017	BUY	$12.0 - $15.0 $15 Million - $18.8 Million	1,250,297	1,250,297 $18.1 Million

Others Institutions Holding CYTK

# of Institutions

397

Shares Held

122M

Call Options Held

3.46M

Put Options Held

1.86M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.09B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account